SAP-001 is Shanton's lead investigational compound with Best-in-Class potential in uncontrolled gout PRINCETON, N.J. , Aug.
5, 2024 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a groundbreaking treatment for refractory and tophaceous gout patients, today announced full enrollment of a Phase 2b study for its investigational drug SAP-001. "Reaching full enrollment is an important milestone in our 6-month gout study" Shanton's CEO Dr. Bing Li said, "as this sets the clock for topline data readout in Q1 2025.
The study aims to show similar good efficacy and safety results that we saw in our Phase 1 and 2a studies in regular gout patients, but now in the more challenging target population of truly refractory patients that often have a more severe form of gout with limited treatment options. The challenge of this study was to just enroll patients that do not respond to a maximum tolerable dose of conventional Xanthine Oxidase Inhibitors such as allopurinol or febuxostat, which we have now accomplished through full enrollment of the Phase 2b study." About Gout Gout is the most common form of inflammatory arthritis, and the second most prevalent metabolic disease caused by too much uric acid in the bloodstream, with over 10 million adult patients diagnosed in the US alone.
1 Hyperuricemia, elevated serum uric acid levels, can over time result in gout when urate crystals are deposited in joints (tophi) and other body tissues, causing inflammatory respons.